{
  "docId": "019de076-4eee-72eb-9f75-bef42550a1c1",
  "docSlug": "3c2d586ebe2940705b3e5004470d76e3",
  "documentTitle": "Kymera | Investor Presentation Deck | 41 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 41,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 1,
  "notes": "Focuses on partnership dynamics and clinical progress.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-4eee-72eb-9f75-bef42550a1c1/19",
  "deckHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1",
  "deckJsonHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1.json",
  "deckAnchorHref": "/decks/019de076-4eee-72eb-9f75-bef42550a1c1#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "Phase 1 results in healthy volunteers and patients support Phase 2 advancement; Sanofi responsible for program development costs; Kymera retains option (before Phase 3) for cost and profit sharing; First development milestone achieved in Q4 2023; $40 million for first patient dosed in HS trial; Additional milestone payable upon first patient dosed in AD trial; Topline data from two ongoing trials expected 1H 2025; Kymera and Sanofi evaluating opportunities to expand indications beyond HS and AD",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2490a1dd-bc35-4916-be2f-65bec5dc17f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "KT-474: Oral Agent with Potential to Achieve Broad, Well-Tolerated Anti-Inflammatory Effect in Multiple Diseases",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fa6825bb-1082-4fdd-9257-a4cb2c76aa3f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 19,
      "from": 10,
      "beatId": "76c0c72b-c82b-4ac5-891b-8e3593c8cc1e",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The deck showcases encouraging clinical data for lead programs.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 19,
      "from": 10,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "481e5a5e-15c9-4f41-910c-aaa935cd7dad",
      "evidence": "The deck showcases encouraging clinical data for lead programs.",
      "position": 1,
      "objective": "What are the potential benefits of Kymera's platform?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}